SNY vs. BMY
Compare and contrast key facts about Sanofi (SNY) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SNY or BMY.
Correlation
The correlation between SNY and BMY is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
SNY vs. BMY - Performance Comparison
Loading data...
Key characteristics
SNY:
0.16
BMY:
0.11
SNY:
0.44
BMY:
0.38
SNY:
1.05
BMY:
1.05
SNY:
0.20
BMY:
0.06
SNY:
0.45
BMY:
0.35
SNY:
9.62%
BMY:
8.46%
SNY:
24.21%
BMY:
31.25%
SNY:
-46.65%
BMY:
-70.62%
SNY:
-13.51%
BMY:
-39.53%
Fundamentals
SNY:
$125.13B
BMY:
$94.81B
SNY:
$2.80
BMY:
$2.54
SNY:
17.84
BMY:
17.37
SNY:
0.82
BMY:
2.26
SNY:
2.77
BMY:
1.99
SNY:
1.47
BMY:
5.45
SNY:
$43.77B
BMY:
$47.64B
SNY:
$31.14B
BMY:
$31.43B
SNY:
$10.09B
BMY:
$16.18B
Returns By Period
In the year-to-date period, SNY achieves a 6.55% return, which is significantly higher than BMY's -20.28% return. Over the past 10 years, SNY has outperformed BMY with an annualized return of 3.81%, while BMY has yielded a comparatively lower -1.06% annualized return.
SNY
6.55%
-0.87%
3.80%
3.82%
4.92%
3.81%
BMY
-20.28%
-14.06%
-22.80%
3.53%
-3.75%
-1.06%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SNY vs. BMY — Risk-Adjusted Performance Rank
SNY
BMY
SNY vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
SNY vs. BMY - Dividend Comparison
SNY's dividend yield for the trailing twelve months is around 4.50%, less than BMY's 5.53% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | 4.50% | 4.22% | 3.83% | 4.22% | 3.80% | 3.61% | 3.46% | 4.29% | 3.67% | 4.03% | 3.79% | 4.19% |
BMY Bristol-Myers Squibb Company | 5.53% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
SNY vs. BMY - Drawdown Comparison
The maximum SNY drawdown since its inception was -46.65%, smaller than the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for SNY and BMY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
SNY vs. BMY - Volatility Comparison
The current volatility for Sanofi (SNY) is 8.13%, while Bristol-Myers Squibb Company (BMY) has a volatility of 10.67%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
SNY vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNY vs. BMY - Profitability Comparison
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sanofi reported a gross profit of 7.72B and revenue of 10.61B. Therefore, the gross margin over that period was 72.8%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sanofi reported an operating income of 2.29B and revenue of 10.61B, resulting in an operating margin of 21.5%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sanofi reported a net income of 1.87B and revenue of 10.61B, resulting in a net margin of 17.7%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.